TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37370125

Group type: EXPERIMENTAL
Intervention: Reading intervention using Accessible Literacy Learning (ALL) strategies, delivered in a one-to-one format over 18 months starting March 2023.
Number of subjects: 40
Study: 37370135

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 340
Study: 37370150

Group type: EXPERIMENTAL
Intervention: Ultrasound-based protocol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional fluid therapy
Number of subjects: 40
Study: 37370174

Group type: COMPARATOR
Intervention: Standard of Care (SoC) TB treatment + placebo
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC) TB treatment + acetylsalicylic acid (ASA)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC) TB treatment + ibuprofen (Ibu)
Number of subjects: 354
Study: 37370204

Group type: EXPERIMENTAL
Intervention: Facilitated allogeneic hematopoietic stem cell transplant with tolerogenic CD8 + /T-cell receptor - facilitating cells (FCR001) and low-dose, nonmyeloablative conditioning.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Facilitated allogeneic hematopoietic stem cell transplant (tolerant participants).
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard-of-care patients on immunosuppression (IS).
Number of subjects: 37
Study: 37370238

Group type: EXPERIMENTAL
Intervention: Telemedicine collaborative care for PTSD
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Shared decision-making tools
Number of subjects: 1071
Study: 37370995

Group type: EXPERIMENTAL
Intervention: MammoWave microwave imaging device
Number of subjects: 600
Study: 37372153

Group type: EXPERIMENTAL
Intervention: AAV9.SMN (Zolgensma) for SMA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAV9.IGHMBP2 for IGHMBP2 disorders
Number of subjects: 0
Study: 37372414

Group type: EXPERIMENTAL
Intervention: Brexanolone (allopregnanolone)
Number of subjects: 0
Study: 37373625

Group type: EXPERIMENTAL
Intervention: E4 15 mg once daily for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37373853

Group type: EXPERIMENTAL
Intervention: Patients with long COVID symptoms (n = 44)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Patients without long COVID symptoms (n = 102)
Number of subjects: 146
Study: 37373857

Group type: EXPERIMENTAL
Intervention: Pneumatic compression combined with standard venous thromboembolism (VTE) therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard venous thromboembolism (VTE) therapy (control group)
Number of subjects: 47
Study: 37374884

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study: 37375656

Group type: EXPERIMENTAL
Intervention: High dose of oligomalt (180 g/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate dose of oligomalt (80 g/day) + maltodextrin (100 g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Maltodextrin (180 g/day)
Number of subjects: 24
Study: 37376480

Group type: EXPERIMENTAL
Intervention: PXVX0047 (Ad4 and Ad7 components administered orally in a single dose to 11 subjects)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control Ad4/Ad7 vaccine (currently in use by the US military, administered to 3 subjects)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PXVX0047 (Ad4 component)
Number of subjects: 14
Study: 37376649

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Tenofovir alafenamide-based regimens (TBR)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Archived major RAMs presence
Number of subjects: 734
Study: 37376804

Group type: EXPERIMENTAL
Intervention: 1 time per week of recreational team handball
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 2 times per week of recreational team handball
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 3 times per week of recreational team handball
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 37376817

Group type: EXPERIMENTAL
Intervention: Subannular repair
Number of subjects: 94
Study: 37376989

Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol <70 mg/dL with >50% LDL cholesterol reduction from baseline
Number of subjects: 2860

Group type: EXPERIMENTAL
Intervention: Target LDL cholesterol <70 mg/dL with <50% LDL cholesterol reduction from baseline
Number of subjects: 2860

Group type: COMPARATOR
Intervention: Target LDL cholesterol 100±10 mg/dL
Number of subjects: 2860
Study: 37377385

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methotrexate 25 mg subcutaneously weekly
Number of subjects: 100
Study: 37377462

Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking Scale - Self Report (CHRT-SR)
Number of subjects: 403
Study: 37377468

Group type: EXPERIMENTAL
Intervention: Telecare-based intervention program (3-month program with online nurse case management, online resource center, discussion forum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual services provided by community centers
Number of subjects: 0
Study: 37377605

Group type: EXPERIMENTAL
Intervention: Autologous iNKT cells combined with PD-1
Number of subjects: 15
Study: 37377613

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily
Number of subjects: 45
Study: 37377890

Group type: EXPERIMENTAL
Intervention: Intravenous RNA-electroporated cMET-directed CAR T cells (1 × 10e8 T cells/dose, up to six infusions)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous RNA-electroporated cMET-directed CAR T cells
Number of subjects: 7
Study: 37378404

Group type: EXPERIMENTAL
Intervention: Ambrisentan treatment
Number of subjects: 83
Study: 37378490

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 37378706

Group type: EXPERIMENTAL
Intervention: Calcified plaque with lipidic materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy and intravascular ultrasound imaging
Number of subjects: 0
Study: 37378754

Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg, 300 mg
Number of subjects: 1072

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1072
Study: 37378806

Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIg) at 2.0 g/kg induction dose followed by maintenance doses of 0.5, 1.0 or 2.0 g/kg every 3 weeks for 24 weeks
Number of subjects: 142
Study: 37378860

Group type: EXPERIMENTAL
Intervention: CC-90001 (100, 200, or 400 mg) administered once daily for 12 weeks
Number of subjects: 16
Study: 37378896

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy or RT after induction chemotherapy (IC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Induction chemotherapy (IC) alone
Number of subjects: 34
Study: 37378966

Group type: EXPERIMENTAL
Intervention: CPVI plus low-voltage-area ablation
Number of subjects: 438

Group type: COMPARATOR
Intervention: CPVI alone
Number of subjects: 438
Study: 37378972

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (varenicline, dual-form nicotine replacement, or their combination) and behavioral smoking cessation intervention with weight management and physical activity support
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group received quitline referrals
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 192
Study: 37378974

Group type: EXPERIMENTAL
Intervention: Support and Problem Solving (SPS) for 6 weeks
Number of subjects: 342

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Case Management (CBCM) for 20 weeks
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Case Management (CBCM) with Fluoxetine for 26 weeks
Number of subjects: 342

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Case Management (CBCM) with Placebo for 26 weeks
Number of subjects: 342

Group type: COMPARATOR
Intervention: Monitoring after remission
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Transition to psychosis
Number of subjects: 342
Study: 37378983

Group type: EXPERIMENTAL
Intervention: 3RP-NF
Number of subjects: 228

Group type: COMPARATOR
Intervention: HEP-NF
Number of subjects: 228
Study: 37379001

Group type: EXPERIMENTAL
Intervention: 10-day course of antibiotics
Number of subjects: 776
Study: 37379055

Group type: EXPERIMENTAL
Intervention: CRCweb (web-based dyadic intervention)
Number of subjects: 20
Study: 37379059

Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both EC and SC
Number of subjects: 60
Study: 37379135

Group type: EXPERIMENTAL
Intervention: Mirikizumab (300 mg)
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Mirikizumab (200 mg)
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study: 37379158

Group type: EXPERIMENTAL
Intervention: Nivolumab plus platinum-based chemotherapy (experimental group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 86
Study: 37379271

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (8 cycles starting day +1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Allogeneic transplant (propensity score-matched cohort)
Number of subjects: 20
Study: 37379430

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 790

Group type: COMPARATOR
Intervention: Platinum-pemetrexed
Number of subjects: 790

Group type: COMPARATOR
Intervention: Comparator EGFR-TKI
Number of subjects: 790
Study: 37379468

Group type: EXPERIMENTAL
Intervention: Ischial containment sockets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subischial sockets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quadrilateral sockets
Number of subjects: 10

Group type: COMPARATOR
Intervention: All socket designs
Number of subjects: 10
Study: 37379470

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37379478

Group type: EXPERIMENTAL
Intervention: 1 sexual partner
Number of subjects: 876

Group type: COMPARATOR
Intervention: 0 sexual partners
Number of subjects: 876

Group type: COMPARATOR
Intervention: 2-5 sexual partners
Number of subjects: 876

Group type: COMPARATOR
Intervention: >5 sexual partners
Number of subjects: 876
Study: 37379495

Group type: EXPERIMENTAL
Intervention: Gilteritinib 120 mg once daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gilteritinib as single-agent maintenance therapy
Number of subjects: 80
Study: 37379502

Group type: EXPERIMENTAL
Intervention: Lazertinib 240 mg once daily orally
Number of subjects: 393

Group type: COMPARATOR
Intervention: Gefitinib 250 mg once daily orally
Number of subjects: 393
Study: 37379532

Group type: EXPERIMENTAL
Intervention: Sputnik V vaccine
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ocrelizumab treatment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall vaccination (Sputnik V or AstraZeneca)
Number of subjects: 94
Study: 37379584

Group type: EXPERIMENTAL
Intervention: Liver transplantation from HIV-positive donors
Number of subjects: 29

Group type: COMPARATOR
Intervention: Liver transplantation from HIV-negative donors
Number of subjects: 29
Study: 37379764

Group type: EXPERIMENTAL
Intervention: Avelumab plus binimetinib 45 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Avelumab plus binimetinib 30 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Talazoparib plus binimetinib 45 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Talazoparib plus binimetinib 30 mg
Number of subjects: 35
Study: 37380019

Group type: EXPERIMENTAL
Intervention: DASH behavioral counseling over 12 months
Number of subjects: 320

Group type: COMPARATOR
Intervention: Education on lung health, asthma, and other general health topics (Control)
Number of subjects: 320
Study: 37380091

Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB) using a 1.1-mm diameter cryoprobe
Number of subjects: 50
Study: 37380156

Group type: COMPARATOR
Intervention: ANDV DNA vaccine (2 mg) in a 3-dose schedule (days 1, 29, 169)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ANDV DNA vaccine (2 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ANDV DNA vaccine (4 mg) in a 3-dose schedule (days 1, 29, 169)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ANDV DNA vaccine (4 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 37380207

Group type: EXPERIMENTAL
Intervention: Perceive, Recall, Plan and Perform (PRPP) intervention, 9 sessions of 45-60 min over 3 weeks
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (baseline measurements of task mastery and cognitive strategy application)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Goal Attainment Scale and Barthel Index
Number of subjects: 3
Study: 37380211

Group type: EXPERIMENTAL
Intervention: TESLA-G (gamified quizzing platform)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-gamified quizzing platform (active control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TESLA-G
Number of subjects: 50
Study: 37380212

Group type: EXPERIMENTAL
Intervention: Outpatient management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home care management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital admission
Number of subjects: 0
Study: 37380226

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) with anticoagulation
Number of subjects: 614

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone without anticoagulation
Number of subjects: 614
Study: 37380301

Group type: EXPERIMENTAL
Intervention: Goflikicept
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 37380364

Group type: EXPERIMENTAL
Intervention: Roxadustat (oral hypoxia-inducible factor prolyl hydroxylase inhibitor), administered three times weekly in-center for 24 weeks.
Number of subjects: 283
Study: 37380519

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study: 37380568

Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM)
Number of subjects: 1201817
Study: 37380598

Group type: EXPERIMENTAL
Intervention: Improved trajectory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-Stable trajectory
Number of subjects: 0
Study: 37380625

Group type: EXPERIMENTAL
Intervention: Continuous pulse oximetry (cSpO) monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37380711

Group type: EXPERIMENTAL
Intervention: Higher plasma corticosteroid levels in the third trimester
Number of subjects: 1503
Study: 37380749

Group type: EXPERIMENTAL
Intervention: Percent body fat in the POPF group (26.90)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Pancreatic duct < 3 mm
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Percent body fat
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Percent body fat ≥ 35%
Number of subjects: 143
Study: 37380821

Group type: EXPERIMENTAL
Intervention: Intravenous infusion using vascular access button (VAB) technology for AZD5991
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37380901

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Devices (PEDs)
Number of subjects: 52
Study: 37380905

Group type: EXPERIMENTAL
Intervention: CCTA and NIRS/IVUS imaging
Number of subjects: 69

Group type: COMPARATOR
Intervention: CCTA
Number of subjects: 69
Study: 37381014

Group type: EXPERIMENTAL
Intervention: Baseline retinal oximetry
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCT-A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Microperimetry
Number of subjects: 41
Study: 37381691

Group type: EXPERIMENTAL
Intervention: Scalp hair regrowth (meaningful regrowth, SALT score ≤20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scalp hair regrowth (meaningful regrowth)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scalp hair regrowth at Week 36
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate scalp hair regrowth
Number of subjects: 0
Study: 37381988

Group type: EXPERIMENTAL
Intervention: rNAPc2 (lower or higher dose)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: rNAPc2
Number of subjects: 160

Group type: COMPARATOR
Intervention: Heparin (standard of care)
Number of subjects: 160
Study: 37382155

Group type: EXPERIMENTAL
Intervention: mRNA vaccines BNT162b2 (Pfizer/BioNTech), mRNA1273 (Moderna) in two and three-dose regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent mRNA vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualization and adjustment of immunosuppressive drugs
Number of subjects: 0
Study: 37382370

Group type: EXPERIMENTAL
Intervention: Low-impact laparoscopy (LIL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 50
Study: 37382408

Group type: EXPERIMENTAL
Intervention: Access flap with xenograft and collagen membrane (test)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Access flap (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 37382794

Group type: EXPERIMENTAL
Intervention: FM-ACT (self-guided digital acceptance and commitment therapy) for 12 weeks, n=39
Number of subjects: 67

Group type: COMPARATOR
Intervention: FM-ST (digital symptom tracking) for 12 weeks, n=28
Number of subjects: 67
Study: 37382825

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 501
Study: 37382891

Group type: EXPERIMENTAL
Intervention: Physical activity (measured by steps taken per day)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Sedentary time (hours per day)
Number of subjects: 419
Study: 37382913

Group type: EXPERIMENTAL
Intervention: Intraoperative Indocyanine Green Angiography (ICGA)
Number of subjects: 10
Study: 37382961

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose and Placebo
Number of subjects: 1132
Study: 37382971

Group type: EXPERIMENTAL
Intervention: Norovirus infection management in kidney transplant recipient
Number of subjects: 1
Study: 37383243

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin/relebactam (IMI/REL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: normal renal function, APACHE II score <15, no vasopressor use, no bacteremia at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vasopressor use, renal impairment, bacteremia at baseline, APACHE II scores ≥15
Number of subjects: 0
Study: 37383290

Group type: EXPERIMENTAL
Intervention: Tenofovir/Levonorgestrel (TFV/LNG) intravaginal ring
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) intravaginal ring
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo intravaginal ring
Number of subjects: 27
Study: 37383763

Group type: EXPERIMENTAL
Intervention: Standard opioid prescription (ten 5 mg tablets oxycodone provided preoperatively)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Restricted opioid prescription (opioid prescription provided only upon patient request postoperatively)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 37383995

Group type: EXPERIMENTAL
Intervention: Wheat soya blend plus (WSB+) during pregnancy and first six months of lactation, and lipid-based nutrient supplement - medium-quantity (LNS-MQ) between 6-23 months of age.
Number of subjects: 2030

Group type: COMPARATOR
Intervention: Control group (no nutritional supplementation).
Number of subjects: 2030
Study: 37384109

Group type: EXPERIMENTAL
Intervention: Probiotic and herbal supplement taken twice a day for 1 month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study: 37384278

Group type: EXPERIMENTAL
Intervention: Microburst VNS in addition to standard anti-seizure medications
Number of subjects: 0
Study: 37384390

Group type: EXPERIMENTAL
Intervention: Automated Messaging (AM) intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 800
Study: 37384392

Group type: EXPERIMENTAL
Intervention: Message-based psychotherapy (n=46)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Video-based psychotherapy (n=37)
Number of subjects: 83
Study: 37384412

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily for 6 weeks
Number of subjects: 10
Study: 37384434

Group type: EXPERIMENTAL
Intervention: Experiential training in emotional processing skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37384482

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
Number of subjects: 119

Group type: COMPARATOR
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders using Seeking Safety
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders (both interventions)
Number of subjects: 119
Study: 37384600

Group type: EXPERIMENTAL
Intervention: Video-based health education intervention
Number of subjects: 41
Study: 37384671

Group type: EXPERIMENTAL
Intervention: Community mobilization, mobile health teams offering MNCH and immunization services, engagement of the private sector, testing of the Sehat Nishani app for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sehat Nishani app
Number of subjects: 0
Study: 37384799

Group type: EXPERIMENTAL
Intervention: Pf 7G8 clone CHMI
Number of subjects: 0
Study: 37384848

Group type: EXPERIMENTAL
Intervention: Zipalertinib at various dose levels (30, 45, 65, 100, and 150 mg orally twice a day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Zipalertinib at 100 mg twice a day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Zipalertinib
Number of subjects: 73
Study: 37384853

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Number of subjects: 0